Cellular senescence demonstrates a striking Jekyll-and-Hyde behavior in pancreatic ductal adenocarcinoma, initially suppressing KRAS-driven tumor formation but later accelerating disease progression. Early in tumorigenesis, oncogene-induced senescence acts as a protective barrier against malignant transformation. However, established cancers exploit senescent cancer-associated fibroblasts within the tumor stroma, which release inflammatory factors through their senescence-associated secretory phenotype, promoting treatment resistance and immune evasion. This paradox extends to cancer treatment itself—chemotherapy inadvertently triggers therapy-induced senescence that contributes to tumor persistence and relapse. The finding illuminates why pancreatic cancer remains so lethal despite decades of research. This dual nature suggests current therapeutic approaches may be counterproductive, as standard treatments inadvertently create senescent cells that fuel long-term cancer survival. The research landscape is shifting toward senolytic drugs that eliminate senescent cells and senomorphic compounds that suppress their harmful secretions. For pancreatic cancer patients facing a five-year survival rate below 10%, understanding senescence timing could revolutionize treatment sequencing and explain why this cancer consistently outsmarts conventional therapies through cellular reprogramming.